Journal
ACTA NEUROPATHOLOGICA
Volume 120, Issue 3, Pages 385-399Publisher
SPRINGER
DOI: 10.1007/s00401-010-0723-9
Keywords
Biomarker; Diagnosis; Alzheimer's disease; Frontotemporal dementia; Lewy bodies; Tau; Tauopathy; TDP-43
Categories
Funding
- NATIONAL INSTITUTE ON AGING [P30AG010124, U19AG010483, P01AG017586] Funding Source: NIH RePORTER
- NIA NIH HHS [P01 AG017586-109002, P30 AG010124, P01 AG017586, P30 AG010124-20, U19 AG010483] Funding Source: Medline
Ask authors/readers for more resources
Ante-mortem diagnosis of neurodegenerative disorders based on clinical features alone is associated with variable sensitivity and specificity, and biomarkers can potentially improve the accuracy of clinical diagnosis. In patients suspected of having Alzheimer's disease (AD), alterations in cerebrospinal fluid (CSF) biomarkers that reflect the neuropathologic changes of AD strongly support the diagnosis, although there is a trade-off between sensitivity and specificity due to similar changes in cognitively healthy subjects. Here, we review the current approaches in using CSF AD biomarkers (total tau, p-tau(181), and A beta 42) to predict the presence of AD pathology, and our recent work using multi-analyte profiling to derive novel biomarkers for biofluid-based AD diagnosis. We also review our use of the multi-analyte profiling strategy to identify novel biomarkers that can distinguish between subtypes of frontotemporal lobar degeneration, and those at risk of developing cognitive impairment in Parkinson's disease. Multi-analyte profiling is a powerful tool for biomarker discovery in complex neurodegenerative disorders, and analytes associated with one or more diseases may shed light on relevant biological pathways and potential targets for intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available